新闻发布

01.05.2021 | Nanion Technologies and InnoVitro

Munich, Germany, May 1st 2021:

Assessing preclinical cardiac contractility without animal use, but with human iPSC-derived cardiomyocytes is not only attractive for people in the cardiac community!

Parliamentary State Secretary Thomas Rachel (representing the Federal Ministry of Education & Research) stopped by InnoVitro headquarters in Juelich to award them with a 200k grant for the support of the new project SMOOTH: “Semi–synthetic Muscle Organoids based On Tissue Hybrids”

Continue Reading

17.04.2020 | Nanion Technologies and NEXEL partner to open a new reference demonstration laboratory in South Korea

Munich, Germany, April 17th 2020: Nanion Technologies GmbH, a leading provider of automated patch clamp and cell monitoring systems, announces the partnership with NEXEL Co., Ltd., specialists in the manufacturing of hiPSC-derived cells. Under the partnership NEXEL will provide demonstration infrastructure in South Korea for Nanion´s CardioExcyte 96 and FLEXcyte 96 cell monitoring systems, while Nanion will provide scientific proficiency in experimental design and assay development.

Continue Reading

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.